This article comes from WeChat public account: interface news (ID: wowjiemian) , author: An Jing
“Due to the rapid development of various institutions, it may be too hasty to evaluate the safety and effectiveness of vaccines.”
Following the United States, Russia, France and Germany, British companies have also announced their participation in the development of new coronavirus vaccines.
According to the announcement by the non-profit organization Epidemic Prevention Innovation Alliance (CEPI) on February 3, British pharmaceutical giant GlaxoSmithKline will In cooperation with CEPI, participated in the development of new coronavirus vaccines.
The announcement shows that GlaxoSmithKline will cooperate with CEPI-funded institutions so that relevant institutions can use GlaxoSmithKline’s vaccine adjuvant technology in the process of developing vaccines.
Vaccine adjuvants can induce the body to produce a long-term, highly efficient specific immune response, improve the body’s protective ability, reduce the amount of immune substances, and reduce the cost of vaccine production.
As the first phase of cooperation, GlaxoSmithKline has signed an agreement with the University of Queensland, Australia. The University of Queensland ranks first in biotechnology in Australia and ninth in the world.
In January 2019, the school signed a cooperation agreement with CEPI and agreed to establish a “molecular clamp” technology vaccine platform to rapidly develop vaccines against various viral pathogens. As part of the agreement, CEPI will provide $ 10.6 million in research costs. The molecular clamp technology is to add a gene to the viral protein to stabilize it, and at the same time let the human body detect a live virus to make antibodies to destroy the virus.
University of Queensland President Howe (Peter Høj) said that researchers at the University of Queensland are developing a new coronavirus vaccine, and GlaxoSmithKline’s vaccine adjuvant will help researchers conduct preclinical experiments to test the effectiveness of the vaccine.
Paul Young, head of the school ’s Department of Chemistry and Space Molecular Biology (Paul Young) previously issued a statement saying that the research team hopes to A vaccine was developed within “the next six months”.
In addition to the University of Queensland, CEPI also signed cooperation agreements with American vaccine company Inovio and biotechnology company Moderna.
The cooperation agreement with Inovio focuses on the development of a DNA vaccine against the Middle East Respiratory Syndrome Coronavirus. Following the outbreak of this new coronavirus outbreak, Inovio’s laboratory in San Diego, California, is also developing related vaccines.
If things go well, the researchers plan to work with Chinese biotech companies to use the vaccine in human trials this summer.
At the same time, according to the cooperation agreement with CEPI, Moderna, which set the IPO record of the largest biomedical company in the United States in 2018, will collaborate with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health in the United States to Coronavirus develops mRNA (messenger RNA) vaccine.
Moderna’s main research and development direction is mRNA technology, that is, after injecting a conductor into the human body, it stimulates human antigens as drugs to fight the virus.
The director of the National Institute of Allergy and Infectious Diseases, Forsyth (Anthony Fauci) said last week that if all goes well, the research team will The first phase of the vaccine will be tested in the “next three months,” or early human trials.
CEPI is an epidemic prevention and control alliance co-founded by the Government of Norway, the Government of India, the Bill & Melinda Gates Foundation, the Wellcome Foundation and the World Economic Forum in Davos in 2017. Diseases targeted by the alliance include Ebola, Lassa virus, Middle East respiratory syndrome, Nipah virus, etc.
In addition to the four projects signed by CEPI, pharmaceutical companies such as Johnson & Johnson have launched their own vaccinesR & D. In other countries, the private foundation Pasteur Institute of France announced last week the establishment of an action group that plans to develop a new coronavirus vaccine within the next 20 months. The action team is expected to use the vaccine in clinical trials by the end of August this year.
German research minister Karlizek also stated last Friday that he expected the vaccine to be successfully developed within “several months”. German biopharmaceutical company CureVac AG will also collaborate with CEPI to develop a new coronavirus vaccine.
Although there are currently many companies and institutions running vaccine development races, Perlman, professor of microbiology, immunology and pediatrics at the University of Iowa, USA Stanley Perlman) Remind that as agencies speed up research and development, they may be overly hasty in assessing vaccine safety and effectiveness.
In addition, after the development of a potential vaccine, the potential vaccine also needs to undergo animal experiments, small-scale and large-scale clinical human experiments to ensure the effectiveness and safety of the vaccine. The time that can be shortened in these steps is very limited, so the final vaccine can be safely put into use “it takes time.”
For example, the chief R & D officer of Johnson & Johnson expects that if the company’s research and development is successful, it will take at least a year to bring the new coronavirus vaccine to the market.
This article comes from WeChat public account: interface news (ID: wowjiemian) , author: An Jing